版权说明 操作指南
首页 > 成果 > 详情

Targeting MyD88: Therapeutic mechanisms and potential applications of the specific inhibitor ST2825

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Liu, Meiqi;Kang, Wenyan;Hu, Zhizhong;Wang, Chengkun*;Zhang, Yang
通讯作者:
Wang, Chengkun;Zhang, Y
作者机构:
[Hu, Zhizhong; Zhang, Yang; Kang, Wenyan; Wang, Chengkun; Wang, CK; Zhang, Y; Liu, Meiqi] Univ South China, Canc Res Inst, Hengyang Med Sch, Chang Sheng Xi Ave 28, Hengyang City 421001, Hunan, Peoples R China.
通讯机构:
[Wang, CK; Zhang, Y ] U
Univ South China, Canc Res Inst, Hengyang Med Sch, Chang Sheng Xi Ave 28, Hengyang City 421001, Hunan, Peoples R China.
语种:
英文
关键词:
MyD88 inhibitor;Anti-inflammatory;ST2825;Immunity;Targeted therapy
期刊:
Inflammation Research
ISSN:
1023-3830
年:
2023
卷:
72
期:
10-11
页码:
2023-2036
基金类别:
This work was supported by the Youth Program of National Natural Science Foundation of China (No. 81500169), the Hunan Province Key Laboratory of Tumour Cellular amp; Molecular Pathology (2016TP1015), and the Key Project of Hunan Provincial Health Commiss [81500169]; Youth Program of National Natural Science Foundation of China [2016TP1015]; Hunan Province Key Laboratory of Tumour Cellular amp; Molecular Pathology [20201921]; Key Project of Hunan Provincial Health Commission
机构署名:
本校为第一且通讯机构
院系归属:
医学院
摘要:
Background: Myeloid differentiation factor-88 (MyD88) is a crucial adapter protein that coordinates the innate immune response and establishes an adaptive immune response. The interaction of the Toll/Interleukin-1 receptor (IL-1R) superfamily with MyD88 triggers the activation of various signalling pathways such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-1), promoting the production of a variety of immune and inflammatory mediators and potentially driving the development of a variety of diseases. Objective: This article will exp...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com